Results 111 to 120 of about 188,223 (344)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

BMC Cancer, 2017
Background The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients.
K. Lisenko, G. Dingeldein, M. Cremer, M. Kriegsmann, A. D. Ho, M. Rieger, M. Witzens-Harig   +6 more
doaj   +1 more source

Rituximab in autoimmune diseases

Biomedicine & Pharmacotherapy, 2004
Modern treatments of autoimmune diseases are based on immunological therapies. Rituximab induces a targeted B-cell depletion in the aim of eradicating autoreactive clones in various autoimmune disorders. Several studies are being undertaken and preliminary reports are very encouraging. The mechanism of action is not evident, but appears to be connected
Vanda Marzocchi, Luigi Virgolini
openaire   +3 more sources

Disease Characteristics and Treatments Associated with Outcome in Primary Angiitis of the Central Nervous System—A Multicenter Cohort Study in 163 Patients

Annals of Neurology, EarlyView.
Objective The aim was to determine patient, disease, and treatment characteristics associated with outcome in patients with primary angiitis of the central nervous system (PACNS) in a large multicenter German cohort. Methods In a retrospective, observational cohort study, we analyzed 163 adult patients who met the diagnostic criteria for PACNS.
Anna Lena Fisse, Nadine Bonberg, Carolin Beuker, Claudia Pfeuffer, Andreas Heidenreich, Christina Krüger, Milani Deb‐Chatterji, Jana Becker, Stefan T. Gerner, Clemens Küpper, Louisa Nitsch, Roxane‐Isabelle Kestner, Lars Udo Krause, Juliane Herm, Alexander Katalinic, André Karch, Ralf Gold, Heinz Wiendl, Wolf‐Rüdiger Schäbitz, Gabor C. Petzold, Waltraud Pfeilschifter, Marius Ringelstein, Thorsten R. Doeppner, Lars Kellert, Hagen B. Huttner, Markus Kraemer, Tim Magnus, Karl Georg Haeusler, Heike Minnerup, Jens Minnerup   +29 more
wiley   +1 more source

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. [PDF]

, 2016
The clinical course of chronic lymphocytic leukaemia (CLL) is heterogeneous, and treatment options vary considerably. The Connect® CLL registry is a multicentre, prospective observational cohort study that provides a real-world perspective on the ...
Farber, Charles M, Flick, E Dawn, Flinn, Ian W, Flowers, Christopher R, Grinblatt, David L, Kay, Neil E, Kipps, Thomas J, Kiselev, Pavel, Kozloff, Mark F, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P, Sullivan, Kristen, Swern, Arlene S, Weiss, Mark A   +15 more
core   +1 more source

High‐Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective Spinal cord (SC) atrophy correlates with and predicts the underlying progressive biology in active and non‐active multiple sclerosis (MS), thereby providing a biomarker for clinical trials and patient management. Initiation of disease‐modifying therapy (DMT) may be followed by early pronounced central nervous system (CNS) volume loss due to ...
Simone Sacco, Nico Papinutto, Vinicius A. Schoeps, Shuiting Cheng, William A. Stern, Haojun Zhao, Antje Bischof, Eduardo Caverzasi, Manula Dombagahawatta, Jeremy Juwono, Amit Akula, Christian Cordano, Alexandra Beaudry‐Richard, Refujia Gomez, Meagan Harms, Adam Santaniello, Riley M. Bove, Jeffrey M. Gelfand, Douglas S. Goodin, Ari J. Green, Jorge R. Oksenberg, Emmanuelle Waubant, Michael R. Wilson, Scott S. Zamvil, Bruce A. C. Cree, Stephen L. Hauser, Roland G. Henry   +26 more
wiley   +1 more source

Clinical-evolutional particularities of the cryoglobulinemic vasculitis in the case of a patient diagnosed with hepatitis C virus in the predialitic phase [PDF]

, 2018
Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term evolution and the gradual appearance of several complications and associated pathologies.
Boldeanu, Lidia, Boldeanu, Mihail V., Caragea, Daniel C., Ciurea, Marius E., Ciurea, Tudorel, Forțofoiu, Maria, Forțofoiu, Mircea C., Popescu-Drigă, Mircea, Pădureanu, Vlad, Rogoveanu, Ion, Streba, Costin, Săndulescu, Larisa, Vere, Cristin C.   +12 more
core   +3 more sources

Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?

Arthritis &Rheumatology, EarlyView.
Objective Although previous studies show that primary prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is effective in patients with rheumatic diseases receiving immunosuppressive treatment, there is limited evidence regarding the optimal timing for prophylaxis withdrawal.
Ju Yeon Kim, Se Rim Choi, Jin Kyun Park, Eun Young Lee, Eun Bong Lee, Jun Won Park   +5 more
wiley   +1 more source

Systemic lupus erythematosis with severe aplastic anemia successfully treated with rituximab and antithymocyte globulin [PDF]

, 1969
Wenbin Liu, Zhiping Hu, Shengyun Lin, Jianghua He, Yuhong Zhou   +4 more
openalex   +1 more source

Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? [PDF]

, 2017
INTRODUCTION: Recent genetic and molecular discoveries regarding alterations in diffuse large B-cell lymphoma (DLBCL) deeply changed the approach to this lymphoproliferative disorder.
Ansuinelli, Michela, DE ANGELIS, Federico, DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio   +4 more
core   +1 more source